Arteriosclerosis and Thrombosis, Vol 14, 1730-1736, Copyright © 1994 by American Heart Association

ARTICLES

Plasma Lp(a) levels correlate with number, severity, and length- extension of coronary lesions in male patients undergoing coronary arteriography for clinically suspected coronary atherosclerosis

T Budde, C Fechtrup, E Bosenberg, C Vielhauer, A Enbergs, H Schulte, G Assmann and G Breithardt
Hospital of the Westfalische Wilhelms-University of Munster, FRG.

The relation between lipoprotein(a) [Lp(a)] as an independent risk factor for coronary atherosclerosis and the severity and extension of angiographically detectable coronary atherosclerotic lesions has not been systematically evaluated. In 118 male patients (54.3 +/- 7.4 years) with suspected coronary artery disease and without a history of myocardial infarction undergoing coronary angiography, the relation between plasma Lp(a) levels and other lipoproteins and the severity and extension of coronary lesions was studied. The coronary angiograms were evaluated in a blinded manner according to three scores: vessel score (0 to 3 points for 0 to 3 vessels with stenoses > or = 70%), stenosis score (0 to 32 points; number and severity of coronary stenoses or lesions), and extent score (0 to 100 points; length-extension of all coronary lesions in relation to the total coronary vessel length). The score values obtained were analyzed for correlations with age and levels of total cholesterol (6.08 +/- 1.26 mmol/L; mean +/- SD), high- density lipoprotein cholesterol (1.04 +/- 0.33 mmol/L), low-density lipoprotein cholesterol (4.18 +/- 1.15 mmol/L), triglycerides (1.88 +/- 1.37 mmol/L), and Lp(a) in plasma (19.5 +/- 22.6 mg/dL). Bivariate correlation analysis resulted in positive correlations between Lp(a) and vessel score (P < .01), stenosis score (P < .01), and extent score (P < .05). With multivariate analyses, besides Lp(a) plasma level (nl), only patient age showed a significant correlation to all three scores used, whereas none of the lipid parameters correlated significantly with all three scores.

This article has been cited by other articles:

				J. McKenney New Perspectives on the Use of Niacin in the Treatment of Lipid Disorders Arch Intern Med, April 12, 2004; 164(7): 697 - 705. [Abstract] [Full Text] [PDF]

				T. Iwamoto, S. Fukuda, S. Shimizu, and M. Takasaki Long-Term Effects of Lipoprotein(a) on Carotid Atherosclerosis in Elderly Japanese J. Gerontol. A Biol. Sci. Med. Sci., January 1, 2004; 59(1): M62 - 67. [Abstract] [Full Text] [PDF]

				M. Artieda, A. Cenarro, A. Ganan, I. Jerico, C. Gonzalvo, J. M. Casado, I. Vitoria, J. Puzo, M. Pocovi, and F. Civeira Serum Chitotriosidase Activity Is Increased in Subjects With Atherosclerosis Disease Arterioscler Thromb Vasc Biol, September 1, 2003; 23(9): 1645 - 1652. [Abstract] [Full Text] [PDF]

				References Circulation, December 17, 2002; 106(25): 3373 - 3421. [Full Text]

				V. Stangl, G. Baumann, and K. Stangl Coronary atherogenic risk factors in women Eur. Heart J., November 2, 2002; 23(22): 1738 - 1752. [Full Text] [PDF]

				N. Komai, R. Morishita, S. Yamada, M. Oishi, S. Iguchi, M. Aoki, M. Sasaki, I. Sakurabayashi, J. Higaki, and T. Ogihara Mitogenic Activity of Oxidized Lipoprotein (a) on Human Vascular Smooth Muscle Cells Hypertension, September 1, 2002; 40(3): 310 - 314. [Abstract] [Full Text] [PDF]

				M. Peltier, M. C. Iannetta Peltier, M. E. Sarano, J.-P. M. Lesbre, J.-L. Colas, and C. M. Tribouilloy Elevated Serum Lipoprotein(a) Level Is an Independent Marker of Severity of Thoracic Aortic Atherosclerosis* Chest, May 1, 2002; 121(5): 1589 - 1594. [Abstract] [Full Text] [PDF]

				O. Klezovitch, C. Edelstein, and A. M. Scanu Stimulation of Interleukin-8 Production in Human THP-1 Macrophages by Apolipoprotein(a). EVIDENCE FOR A CRITICAL INVOLVEMENT OF ELEMENTS IN ITS C-TERMINAL DOMAIN J. Biol. Chem., December 7, 2001; 276(50): 46864 - 46869. [Abstract] [Full Text] [PDF]

				T. Inoue, T. Uchida, H. Kamishirado, K. Takayanagi, and S. Morooka Antibody against oxidized low density lipoprotein may predict progression or regression of atherosclerotic coronary artery disease J. Am. Coll. Cardiol., June 1, 2001; 37(7): 1871 - 1876. [Abstract] [Full Text] [PDF]

				A Enbergs, R Burger, H Reinecke, M Borggrefe, G Breithardt, and S Kerber Prevalence of coronary artery disease in a general population without suspicion of coronary artery disease: angiographic analysis of subjects aged 40 to 70 years referred for catheter ablation therapy Eur. Heart J., January 1, 2000; 21(1): 45 - 52. [Abstract] [PDF]

				M. Erren, H. Reinecke, R. Junker, M. Fobker, H. Schulte, J. O. Schurek, J. Kropf, S. Kerber, G. Breithardt, G. Assmann, et al. Systemic Inflammatory Parameters in Patients With Atherosclerosis of the Coronary and Peripheral Arteries Arterioscler Thromb Vasc Biol, October 1, 1999; 19(10): 2355 - 2363. [Abstract] [Full Text] [PDF]

				K. J. Harjai Potential New Cardiovascular Risk Factors: Left Ventricular Hypertrophy, Homocysteine, Lipoprotein(a), Triglycerides, Oxidative Stress, and Fibrinogen Ann Intern Med, September 7, 1999; 131(5): 376 - 386. [Abstract] [Full Text] [PDF]

				S. Allen, S. Khan, S.-p. Tam, M. Koschinsky, P. Taylor, and M. Yacoub Expression of adhesion molecules by Lp(a): a potential novel mechanism for its atherogenicity FASEB J, December 1, 1998; 12(15): 1765 - 1776. [Abstract] [Full Text]

				R. Morishita, S. Yamada, K. Yamamoto, N. Tomita, I. Kida, I. Sakurabayashi, A. Kikuchi, Y. Kaneda, R. Lawn, J. Higaki, et al. Novel Therapeutic Strategy for Atherosclerosis : Ribozyme Oligonucleotides Against Apolipoprotein(a) Selectively Inhibit Apolipoprotein(a) But Not Plasminogen Gene Expression Circulation, November 3, 1998; 98(18): 1898 - 1904. [Abstract] [Full Text] [PDF]

				W. Y. Craig, L. M. Neveux, G. E. Palomaki, M. M. Cleveland, and J. E. Haddow Lipoprotein(a) as a risk factor for ischemic heart disease: metaanalysis of prospective studies Clin. Chem., November 1, 1998; 44(11): 2301 - 2306. [Abstract] [Full Text] [PDF]

				D. A. Bellinger, J. K. Williams, M. R. Adams, E. K. Honore, and D. E. Bender Oral Contraceptives and Hormone Replacement Therapy Do Not Increase the Incidence of Arterial Thrombosis in a Nonhuman Primate Model Arterioscler Thromb Vasc Biol, January 1, 1998; 18(1): 92 - 99. [Abstract] [Full Text] [PDF]

				P. N. Hopkins, L. L. Wu, S. C. Hunt, B. C. James, G. M. Vincent, and R. R. Williams Lipoprotein(a) Interactions With Lipid and Nonlipid Risk Factors in Early Familial Coronary Artery Disease Arterioscler Thromb Vasc Biol, November 1, 1997; 17(11): 2783 - 2792. [Abstract] [Full Text]

				J. H. Stein and R. S. Rosenson Lipoprotein Lp(a) Excess and Coronary Heart Disease Arch Intern Med, June 9, 1997; 157(11): 1170 - 1176. [Abstract] [PDF]

				M.-R. Taskinen, J. Puolakka, T. Pyorala, H. Luotola, M. Bjorn, J. Kaariainen, S. Lahdenpera, and C. Ehnholm Hormone Replacement Therapy Lowers Plasma Lp(a) Concentrations: Comparison of Cyclic Transdermal and Continuous Estrogen-Progestin Regimens Arterioscler Thromb Vasc Biol, October 1, 1996; 16(10): 1215 - 1221. [Abstract] [Full Text]

				R. Carmena, S. Lussier-Cacan, M. Roy, A. Minnich, A. Lingenhel, F. Kronenberg, and J. Davignon Lp(a) Levels and Atherosclerotic Vascular Disease in a Sample of Patients With Familial Hypercholesterolemia Sharing the Same Gene Defect Arterioscler Thromb Vasc Biol, January 1, 1996; 16(1): 129 - 136. [Abstract] [Full Text]

				S. Frank, S. Durovic, K. Kostner, and G. M. Kostner Inhibitors for the In Vitro Assembly of Lp(a) Arterioscler Thromb Vasc Biol, October 1, 1995; 15(10): 1774 - 1780. [Abstract] [Full Text]

				R. Morishita, M. Sakaki, K. Yamamoto, S. Iguchi, M. Aoki, K. Yamasaki, K. Matsumoto, T. Nakamura, R. Lawn, T. Ogihara, et al. Impairment of Collateral Formation in Lipoprotein(a) Transgenic Mice: Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene Circulation, March 26, 2002; 105(12): 1491 - 1496. [Abstract] [Full Text] [PDF]